Clinical Trials
12 trialsNCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT02012231 2020-10-19
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Terminated
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00804830 2018-08-28
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
Phase 2 Terminated
NCT00416949 2018-07-18
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated
NCT00115739 2014-04-21
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00077103 2010-06-11
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 1/2 Terminated